Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

A Blood Substitute Gets Bloodied


In Business This Week

A BLOOD SUBSTITUTE GETS BLOODIED

NOT SO FAST: BAXTER INTERNATIONAL ENDED A LATE-STAGE PATIENT TRIAL in the U.S. of its HemAssist blood substitute when it discovered that trauma patients given the product in the hospital were dying at a rate greater than a control group and even higher than normal mortality rates. But Baxter believes the product can still work when administered to patients earlier in their treatment. So it is continuing trials in Europe on trauma patients who would be given HemAssist in the ambulance following a major car accident or gunshot wound, and in the U.S. on patients undergoing elective surgery. Officials expect to have HemAssist on the market by late 1999 or early 2000. Sanford C. Bernstein analyst Kenneth Abramowitz figures that the market may now be 25% smaller than the $2 billion to $4 billion he had expected.EDITED BY KELLEY HOLLAND


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus